by Timothy W.L. Wong. / "July 2000." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2000. / Includes bibliographical references (p. 200-238). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Chi Tian-yi. / "July 2002." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2002. / Includes bibliographical references (p. 213-257). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Lo Kwok-Wai. / Thesis (Ph.D.)--Chinese University of Hong Kong, 1997. / Includes bibliographical references (p. 171-199). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web.

Introdução/Objetivo: Existem evidências indicando que a resposta virológica sustentada (RVS) ao tratamento com interferon pode estar associada com menor incidência de carcinoma hepatocelular (CHC) em pacientes com cirrose causada pelo vírus da hepatite C (VHC). O objetivo do presente estudo foi comparar a incidência de CHC em cirróticos com RVS versus sem RVS. Métodos: Foram selecionados 85 pacientes com cirrose compensada (Child A) secundária ao VHC, confirmada por biópsia, sem quaisquer outras causas de doença hepática. Todos foram submetidos a tratamento com interferon ± ribavirina por pelo menos 24 semanas. Antes do tratamento nenhum paciente apresentava evidência de CHC à ultrassonografia abdominal (US). RVS foi definida como RNA do VHC negativo (PCR qualitativo com limite de detecção de 50 UI/ml) 24 semanas após o final do tratamento. Foram incluídos apenas pacientes com seguimento semestral com US e alfa-fetoproteína e anual com PCR por mais de 12 meses após o final do tratamento. O CHC foi diagnosticado por biópsia ou achados coincidentes de lesão focal com diâmetro superior a 2cm na US e tomografia computadorizada helicoidal trifásica com sinais de hipervascularização arterial. Resultados: Dos 85 pacientes, 38 (45%) alcançaram RVS e 47 (55%) não. A média do seguimento em pacientes com RVS versus sem RVS foi de 32,1 ± 20 meses (variação: 12-84 meses) e 28,2 ± 18 meses (variação: 12-96 meses), respectivamente (P=0,51). O CHC foi diagnosticado em 1 (3%) dos 38 pacientes com RVS e 8 (17%) dos 47 pacientes sem RVS (P=0,02; Razão de chance: 0,13; Intervalo de confiança de 95%: 0,006-0,9). As características pré-tratamento foram semelhantes entre os pacientes com e sem RVS, tanto demográficas (idade e sexo) quanto clínicas (Child A, média da dose total de interferon e tempo de seguimento). Além da ocorrência de CHC, a única outra variável com diferença significativa encontrada entre os grupos com e sem RVS foi o percentual de pacientes com genótipo 1 (13% versus 35%, respectivamente; P = 0,04). Comparando-se os pacientes com e sem CHC, a única variável com diferença estatisticamente significativa encontrada foi o percentual de RVS (11% versus 49%, respectivamente; P = 0,03). Conclusões: Pacientes com cirrose pelo VHC que atingem RVS têm menor incidência de CHC quando comparados àqueles sem RVS. A única diferença entre os grupos com e sem CHC foi a ocorrência de RVS. Este achado indica que a ausência do VHC pode tanto representar fator protetor direto contra o CHC, quanto servir como marcador indireto para identificar cirróticos com menor probabilidade de desenvolver CHC. / Background/Aim: There is strong evidence that sustained virologic response (SVR) to interferon treatment has an impact on the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HVC) related cirrhosis. The aim of this study was to compare the rate of HCC among HCV cirrhotics with vs without SVR. Methods: Eighty five biopsy proven cirrhotic patients with HCV infection (PCR positive), without any other form of liver disease were included. All were treated with interferon (IFN) ± ribavirin (RBV) for at least 24 weeks. Before treatment, all patients were compensated (Child A) and had no evidence of HCC on abdominal ultrasound (US). None had previous hepatic decompensation. SVR was defined as negative HCV-RNA (qualitative PCR with a limit of detection of 50 IU/ml) 24 weeks after end of treatment. Patients followed every 6 months with US and alpha-fetoprotein (AFP) for > 12 months after end of therapy were included. HCC was diagnosed by liver biopsy and/or coincident findings of focal lesion > 2 cm on US and spiral CT with arterial hypervascularization. Results: Thirty eight (45%) were SVRs and 47 (55%) were not. Mean follow-up was 32,1 ± 20 months (range:12-84 months) in SVRs vs 28,2 ± 18 months (range:12-96 months) in no-SVRs (P=0.51). HCC was diagnosed in 1 (3%) of 38 SVRs vs 8 (17%) of 47 patients without SVR (P=0.02; OR:0.13, 95% CI:0.006-0.9). All had similar pre-treatment characteristics (age, sex, liver function, Child A, total interferon dose and follow-up time). Besides HCC incidence, the only significant difference between SVRs and no-SVRs was the rate of genotype 1 (13% vs 35%, respectively, P = 0.04). Comparing patients with and without HCC, the only significant difference was found in the rate of SVR (11% vs 49%, respectively; P = 0,03). Conclusion: HCV cirrhotics with SVR have a lower incidence of HCC compared to those without SVR. The only difference between the groups with and without HCC was the rate of SVR. This finding may indicate that either absence of HCV-RNA truly protects against HCC, or acts as surrogate marker to identify cirrhotics that have a low probability of HCC development on long-term follow-up.

子宮内膜癌是最常见的妇科恶性肿瘤，其中有80%属于子宮内膜腺样癌，这一癌症发病的分子机制尚未清楚。研究表明，癌基因表达异常或者功能异常在肿瘤的发生发展过程中具有重要的作用。另一方面，抑癌基因在肿瘤细胞中特异性甲基化失活通常导致细胞恶性转变和肿瘤的发生。本实验将阐明癌基因阴阳1和抑癌基因PCDH10在人类子宮内膜腺样癌发病中的作用。 / 本实验第一部分研究多功能转录因子阴阳1（YY1）在子宮内膜腺样癌发病过程中的作用。首先本实验证实YY1在子宮内膜腺样癌临床标本和癌细胞系中均明显表达上调，并且上调的程度与肿瘤的FIGO分期相关。接着体外细胞培养和裸鼠荷瘤模型的实验均提示抑制YY1 表达可抑制癌细胞增殖和体外迁移，而过表达YY1则促进癌细胞增殖。这些结果表明YY1在子宮内膜腺样癌发病中具有促进作用。进一步全细胞基因组转录谱分析提示YY1 介入子宮内膜腺样发病的各个方面，并通过抑制抑癌基因APC的表达发挥发挥重要作用。深入的分子机制研究发现一个新的表观抑制作用模型：YY1可募集EZH2等多梳蛋白到APC启动子区并导致后者组蛋白3赖氨酸27上三甲基化，从而抑制APC基因转录。此外，本实验还发现YY1在子宮内膜腺样癌的表达增高是由于微小RNA，miR-193a-5p，在此癌中表达下降所导致的。所以，本实验第一部分的结果揭示了miR-193a-5p-YY1-APC这条全新的信号通路在子宮内膜腺样癌发病中发挥重要作用，并可作为潜在的治疗靶点。 / 本实验第二部分鉴定出PCDH10作为子宮内膜腺样癌一个新的抑癌基因。通过5-氮杂-2'-氧胞嘧啶处理和亚硫酸氢钠测序的方法，我们证实抑癌基因PCDH10在子宮内膜腺样癌中失活是由于其启动子区DNA甲基化所致，并且这种DNA甲基化介导的PCDH10表达沉默在子宮内膜腺样癌临床标本和癌细胞系中很常见，但不存在于正常子宮内膜组织。另外，在子宮内膜腺样癌细胞系体外实验中恢复PCDH10的表达可抑制细胞增殖、单细胞克隆形成，促进细胞凋亡。 同时在体实验荷瘤模型中恢复PCDH10的表达也可抑制肿瘤细胞增殖，这些结果与其肿瘤抑制功能相符。 / 总之，本实验结果阐明了YY1和PCDH10在子宮内膜腺样癌发病过程中新的作用，拓展了子宮内膜腺样癌发病分子机制的研究并为其药物治疗提供了潜在的靶点。 / Endometrial cancer is the most common gynecologic malignancy and about 80% of these cancers are endometrial Endometrioid carcinoma (EEC). The molecular mechanisms underlying EEC tumorigenesis are under-explored. Aberrant expression and function of oncogenes promote tumor development by modulating many aspects of tumor cell growth. On the other hand, tumor specific promoter methylation on tumor suppressor genes (TSG), which are generally unmethylated in normal cells, usually initiate and promote malignant transformation and cancer initiation. Our study aims to characterize the functions of an oncogenic transcription factor Yin Yang 1 (YY1) and a novel tumor suppressor gene PCDH10 in Human Endometrioid Endometrial Adenocarcinoma. / In the first part of our study, we investigated the function of a multifunctional TF, YY1 in EEC tumorigenesis. We demonstrated YY1 is up-regulated in EEC cell lines and primary tumors and its expression is associated with FIGO stages. Depletion of YY1 inhibits EEC cell proliferation and migration both in vitro and in vivo whereas over-expression of YY1 promotes EEC cell growth. These results suggest that YY1 functions as an onocogenic factor in EEC. Transcriptome analysis revealed a significant effect of YY1 on critical aspects of EEC tumorigenesis and its down-regulation of APC transcripts. Further mechanistic investigation uncovered a new epigenetic silencing mode of Adenomatosis Polyposis Coli (APC) by YY1 through recruitment of EZH2 and trimethylation of histone 3 lysine 27 in its promoter region. Additionally, YY1 over-expression was found to be a consequence of miR-193a-5p down-regulation through direct miR-193a-5p-YY1 interplay. Our results therefore established a novel miR-193a-5p-YY1-APC regulatory axis contributing to EEC development, which may serve as future intervention target. / In the second part of our study, we identified PCDH10 as a novel tumor suppressor gene in EEC. By using bisulfate genomic sequencing combined with pharmacologic demethylation drug treatment, we elucidated that PCDH10 inactivation in EEC is a consequence of DNA hypermethylation on its promoter region. Further study suggested that hypermethylation-mediated PCDH10 silencing was a common event in EEC cell lines and clinical samples, but not in normal endometrial tissues. Restoration of PCDH10 expression in EEC cells suppressed cell proliferation, inhibited single cell colony formation and induced cell apoptosis; moreover, overexpression of PCDH10 inhibited EEC xenograft tumor growth in vivo.These results suggest PCDH10 acts as a tumor suppressor. / Together, our results reveal the novel functions of YY1 and PCDH10 in EEC. These findings add novel insights into the molecular mechanisms of EEC development and progression, which may serve as potential therapeutic targets for this disease. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Yang, Yihua. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2012. / Includes bibliographical references (leaves 170-186). / Abstracts also in Chinese. / TITLE --- p.I / ABSTRACT --- p.III / ACKNOWLEDGEMENTS --- p.VII / PUBLICATION --- p.IX / ABBREVIATIONS --- p.X / LIST OF FIGURES --- p.XIII / LIST OF TABLES --- p.XVI / TABLES OF CONTENT --- p.XVII / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Endometrioid Endometrial Adenocarcinoma (EEC) --- p.1 / Chapter 1.1.1 --- Epidemiology --- p.2 / Chapter 1.1.2 --- Etiology and risk factors --- p.3 / Chapter 1.1.3 --- Treatment and prognosis --- p.8 / Chapter 1.1.4 --- Molecular Mechanisms --- p.9 / Chapter 1.1.5 --- APC and Wnt/β-catenin signaling pathway --- p.12 / Chapter 1.1.6 --- Summary --- p.18 / Chapter 1.2 --- Epigenetic modifications and EEC --- p.20 / Chapter 1.2.1 --- Epigenetic modifications --- p.20 / Chapter 1.2.2 --- Epigenetic and cancer --- p.21 / Chapter 1.2.5 --- Summary --- p.30 / Chapter Chapter 2 --- Material and Method --- p.31 / Chapter 2.1 --- Tissue samples --- p.31 / Chapter 2.2 --- Cell culture --- p.32 / Chapter 2.3 --- Cell proliferation assays --- p.33 / Chapter 2.4 --- Cell migration assay --- p.34 / Chapter 2.5 --- 3-deazaneplanocin A (Dznep) or 5-aza-2'-deoxycytidine (5-aza) treatment --- p.34 / Chapter 2.6 --- Computational prediction --- p.35 / Chapter 2.7 --- Cell cycle assay --- p.35 / Chapter 2.8 --- Apoptosis assay --- p.36 / Chapter 2.9 --- Total RNAs, Total proteins and Genomic DNA extraction --- p.36 / Chapter 2.10 --- Bisulfite Genomic Sequencing --- p.38 / Chapter 2.11 --- Oligonucleotides --- p.39 / Chapter 2.12 --- RT-PCR, Semi-quantitative PCR and Real-time PCR --- p.41 / Chapter 2.13 --- microRNA validation --- p.43 / Chapter 2.14 --- Plasmid construction --- p.43 / Chapter 2.15 --- Transfection --- p.45 / Chapter 2.16 --- Luciferase reporter assay --- p.45 / Chapter 2.17 --- Western blotting --- p.46 / Chapter 2.18 --- Immunofluorescence ( IF ) --- p.48 / Chapter 2.19 --- Immunohistochemistry (IHC) --- p.50 / Chapter 2.20 --- ChIP assay --- p.53 / Chapter 2.21 --- Sequencing and base calling --- p.55 / Chapter 2.22 --- Read mapping to genome with splice-aware aligner sequenced --- p.55 / Chapter 2.23 --- Xenograft mouse model --- p.55 / Chapter 2.24 --- Statistical analysis --- p.57 / Chapter Chapter 3 --- Yin Yang 1 Plays an Oncogenic Role in Human Endometrioid Endometrial Adenocarcinoma --- p.58 / Chapter 3.1 --- YIN YANG 1(YY1) --- p.58 / Chapter 3.1.1 --- YY1 structure --- p.58 / Chapter 3.1.2 --- YY1 function --- p.59 / Chapter 3.1.3 --- YY1 and epigenetic --- p.61 / Chapter 3.1.4 --- YY1 and cancer --- p.62 / Chapter 3.1.5 --- Regulation of YY1 expression and activity --- p.66 / Chapter 3.2 --- Results --- p.68 / Chapter 3.2.1 --- YY1 is up-regulated in EEC lines and localizes in nuclei of EEC cells --- p.68 / Chapter 3.2.2 --- YY1 expression level is associated with EEC clinicopathological features --- p.72 / Chapter 3.2.3 --- Knock-down of YY1 by RNAi inhibits EEC cell proliferation and migration --- p.77 / Chapter 3.2.4 --- Ectopic expression of YY1 promotes EEC cell proliferation --- p.84 / Chapter 3.2.5 --- YY1 does not affect EEC cell cycle and cell apoptosis --- p.91 / Chapter 3.2.6 --- Genome-wide characterization of YY1-mediated transcriptome changes --- p.94 / Chapter 3.2.7 --- Gene Ontology analysis of YY1 targets on EEC tumorigenesis --- p.98 / Chapter 3.2.8 --- YY1 inhibits APC gene expression and functions --- p.101 / Chapter 3.2.9 --- YY1 inhibits APC expression through recruiting EZH2 and causing H3K27me3. --- p.105 / Chapter 3.2.10 --- Knock-down of YY1 does not change DNA methylation status of CpG island of APC gene --- p.117 / Chapter 3.2.11 --- SiYY1 oligo injection inhibits tumor grows in vivo --- p.119 / Chapter 3.2.12 --- miR-193a-5p is down-regulated in EEC cell lines and clinical samples --- p.126 / Chapter 3.2.13 --- miR-193a-5p targets YY1 3’UTR and inhibits YY1 expression --- p.128 / Chapter 3.2.14 --- miR-193a-5p inhibits tumor grow in vivo --- p.133 / Chapter 3.3 --- Discussion --- p.136 / Chapter 3.3.1 --- YY1 oncogenic functions in EEC --- p.136 / Chapter 3.3.2 --- YY1 epigenetically silences APC --- p.138 / Chapter 3.3.3 --- miR-193a-5p down-regulates YY1 in EEC --- p.139 / Chapter 3.4 --- Conclusion --- p.141 / Chapter Chapter 4 --- The tumor suppressive functions of PCDH10 in Human Endometrioid Endometrial Adenocarcinoma --- p.143 / Chapter 4.1 --- Introduction --- p.143 / Chapter 4.1.1 --- PCDH10 structure and function --- p.143 / Chapter 4.1.2 --- PCDH10 and tumor --- p.146 / Chapter 4.1 --- Results --- p.149 / Chapter 4.2.1 --- PCDH10 is down-regulated in EEC cell lines and clinical samples --- p.149 / Chapter 4.2.2 --- PCDH10 is hypermethylated in EEC cell lines and clinical samples --- p.150 / Chapter 4.2.3 --- Pharmacologic demethylation restores PCDH10 expression in EEC cell lines --- p.152 / Chapter 4.2.4 --- Ectopic over-expression of PCDH10 inhibits EEC cell proliferation --- p.154 / Chapter 4.2.5 --- PCDH10 over-expression induces EEC cell apoptosis --- p.161 / Chapter 4.2.6 --- PCDH10 over-expression inhibits tumor grows in vivo --- p.166 / Chapter 4.3 --- Discussion and future plan --- p.169 / REFERENCE --- p.170

Chiu Hoi Shan Clarissa. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 110-126). / Abstracts in English and Chinese. / Abstract in English --- p.i / Abstract in Chinese --- p.iii / Acknowledgement --- p.iv / List of Abbreviations --- p.v / List of Tables --- p.vi / List of Figures --- p.viii / Introduction and Objectives / Hepatocellular Carcinoma / Epidemiology --- p.1 / Sex and Age --- p.1 / Geographic distibution --- p.2 / Risk factors of HCC --- p.2 / Mortality from liver cancer --- p.4 / Treatment for HCC --- p.4 / Tumor markers --- p.5 / Alpha-fetoprotein / Structure --- p.5 / Physiological Functions of AFP --- p.7 / Re-expression of AFP in Adult --- p.7 / Re-expression of AFP in HCC --- p.8 / Isoforms of AFP --- p.8 / Specific AFP isoform in HCC --- p.9 / Sialic Acid --- p.11 / Sialyltransferase / "Galβ 1,4GlcnAc α2,6-sialyitransferase" --- p.12 / "Characterization of ST2,6Gal I" --- p.12 / "Expression of ST2,6Gal I" --- p.12 / "General features of ST2,6Gal I Activity" --- p.15 / Relationship Between AFP isoforms and ST2，6Gal in Fetal Mouse Model --- p.15 / "Change in ST2,6GaI I Activity in Transgenic Mouse Models of HCC" --- p.16 / "Study of Activity of ST2,6Gal I in Colon Carcinoma" --- p.16 / Objective of the Project --- p.18 / Chapter Chapter 1 --- Formation of Monosialyated AFP by Hepatoma Cells / Chapter 1.1 --- Introduction --- p.21 / Chapter 1.2 --- Materials and Methods --- p.23 / Chapter 1.3 --- Results / Chapter 1.3.1 --- AFP obtained from cell culture --- p.34 / Chapter 1.3.2 --- IEF for AFP in cell culture medium --- p.34 / Chapter 1.3.3 --- SDS-PAGE analysis of AFP --- p.34 / Chapter 1.3.4 --- Stability of AFP isoforms after secreted to cell culture medium --- p.39 / Chapter 1.3.5 --- Comparison of the AFP isoforms between liver tissues and serum --- p.38 / Chapter 1.4 --- Discussion / Chapter 1.4.1 --- Origin of the extracellular msAFP - in vitro Model --- p.43 / Chapter 1.4.2 --- Origin of circulating msAFP - in vivo Model --- p.44 / Chapter 1.5 --- Conclusion --- p.46 / Chapter Chapter 2 --- "Presence of msAFP in the serum of HCC patient is a Consequence of Decrease in the Activity of ST2, / Chapter 2.1 --- Introduction --- p.47 / Chapter 2.2 --- Materials and Methods --- p.49 / Chapter 2.3 --- Results / Chapter 2.3.1 --- Semi-quantitation of msAFP --- p.61 / Chapter 2.3.2 --- Evaluation of the ST2，6Gal I Assay --- p.65 / Chapter 2.3.3 --- "Measurements and comparisons of the activity of ST2,6Gal I in non-tumor and tumor tissue" --- p.65 / Chapter 2.3.4 --- "Evaluation of the RT-PCR ELISA for semi-quantitation and comparisons of ST2,6Gal I mRNA levels" --- p.75 / Chapter 2.3.5 --- "Semi-quantitation and comparisons of ST2,6Gal I mRNA levels in the non-tumor and tumor tissues" --- p.84 / Chapter 2.3.6 --- Correlations between the markers --- p.87 / Chapter 2.4 --- Discussion / Chapter 2.4.1 --- "Overproduction of AFP, a possible cause for increased msAFP formation" --- p.99 / Chapter 2.4.2 --- "Decrease of ST2,Gal I activity, a possible cause for increased msAFP formation" --- p.100 / Chapter 2.4.3 --- "ST2,6Gal I activity in tumor is not regulated at transcriptional level" --- p.102 / General Discussion / Origin of blood stream msAFP --- p.103 / Physiological Mechanism for the formation of msAFP in HCC --- p.104 / Regulation of ST2，6Gal I activity in HCC --- p.105 / "Comparison between the ST2,6GaI I activities in human HCC and Colon Cancer" --- p.107 / Conclusion and Future studies / Conclusion --- p.108 / Future studies --- p.109 / References --- p.110

Made available in DSpace on 2018-08-01T23:26:20Z (GMT). No. of bitstreams: 1 tese_9286_Dissertação Helenita Mameri.pdf: 1826115 bytes, checksum: 66558042e19caabceb00824ac84ab813 (MD5) Previous issue date: 2015-10-09 / A prevalência do câncer de cabeça e pescoço (cavidade bucal, faringe e laringe) tem aumentado no Brasil na última década, sendo o carcinoma de células escamosas o mais comum. Seu tratamento pode causar severas sequelas funcionais e estéticas, com um impacto significante na qualidade de vida e saúde psicológica desses pacientes. Objetivo: este trabalho buscou relacionar o estilo de vida de indivíduos com o desenvolvimento do carcinoma espinocelular (CEC) de cabeça e pescoço (cavidade bucal, faringe e laringe). Metodologia: um estudo retrospectivo com pacientes portadores do câncer. A pesquisa foi realizada em dois hospitais públicos de referência na cidade de Vitória, Espírito Santo, Brasil, no período de novembro de 2011 a novembro de 2013. Foram incluídos no estudo 97 pacientes portadores de CEC de cabeça e pescoço, e a amostragem foi selecionada por conveniência (51 em cavidade bucal e lábio, 24 em orofaringe, 3 em hipofaringe, 16 em laringe e 2 nasais). Os pacientes foram entrevistados quanto a dados sociodemográficos; hábitos de tabagismo e etilismo (no momento do diagnóstico e após seis meses); hábitos de higiene bucal e tratamento principal. A análise estatística foi descritiva, teste de Qui-quadrado e Exato de Fischer. Resultados: o desenvolvimento das neoplasias está associado a fatores de risco ambientais e de estilo de vida. Houve associação significativa entre o hábito de fumar e o estadiamento dos tumores (0,039) e com o tratamento principal (0,036). De um total de 97 pacientes, 34 vieram a óbito como causa o CEC de cabeça e pescoço (35,1%). Conclusão: Confirmando o tabagismo e o etilismo como fatores de risco para o CEC de cabeça e pescoço, compreendeu-se que quanto maior o tempo de exposição a esses riscos e sua quantidade habitual, há maior propensão ao desenvolvimento do carcinoma de cabeça e pescoço. Isso é importante também na medida em que os gastos com a saúde e no setor público tornam-se elevados. Então, mudanças de hábitos de vida como abstinência do fumo e do álcool são os melhores métodos de prevenção da doença, já que são os principais fatores de risco

Made available in DSpace on 2014-06-11T19:30:59Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-07-28Bitstream added on 2014-06-13T18:41:22Z : No. of bitstreams: 1 bertini_f_dr_sjc.pdf: 1210131 bytes, checksum: e1b2631d7475ffa42f03933df9b818c8 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / O carcinoma epidermóide (CE) representa 95% das neoplasias malignas bucais, sendo língua e assoalho as localizações intra-orais mais comuns. A angiogênese e a linfangiogênese estão relacionadas com desenvolvimento, disseminação e agressividade dos tumores. O objetivo deste estudo foi avaliar a relação entre as características histológicas, densidade microvascular sanguínea (MDV) e linfática (MDL) e proliferação celular no carcinoma epidermóide intra-oral (CEI). Sessenta casos de CEI, sendo 30 de assoalho bucal e 30 de língua, foram analisados e comparados quanto à gradação histológica de malignidade, a expressão do VEGF (fator de crescimento vascular endotelial) VEGF-C (fator de crescimento vascular endotelial - C) e sua correlação com a MDV e MDL. Verificou-se predomínio do gênero masculino em ambas as localizações, assim como da raça leucoderma. Quanto à gradação de malignidade, 73,3% dos casos de carcinoma epidermóide de língua e 96,67% dos casos de assoalho foram considerados muito agressivos. Foi notado um índice de proliferação celular médio maior nos casos de assoalho, entretanto, a diferença com relação à língua não foi estatisticamente significante. A maioria dos carcinomas avaliados teve ausência de marcação para VEGF(63,33% em língua e 70% em assoalho) e marcação positiva para VEGF-C (73,33% em língua e 79,31% em assoalho). A MDL foi maior nos casos de língua, com diferença significativa entre as regiões. Verificou-se que altos valores de MDV ocorrem nos casos com maior proliferação celular, o mesmo não acontecendo com a MDL. Não houve relação dos fatores de crescimento VEGF e VEGF-C com a MDV e MDL respectivamente. Assim pode-se concluir que: a gradação histológica de malignidade é maior nos casos de assoalho do que nos de língua; o índice de proliferação celular é semelhante nas duas regiões; a maioria... / Squamous cell carcinoma (SCC) represents 95% of the oral malignant neoplasias, being the tongue and the floor of the mouth the most common intraoral regions. The angiogenesis is essential to various pathological processes such as the development and dissemination of tumors as well as its agressivity. On the other hand, the lymphangiogenesis would be important in the development of tumor metastasis. The objective of this study is to evaluate the relation among histological characteristics, lymphatic and blood microvascular density and cell proliferation in intraoral squamous cell carcinoma (OSCC). Sixty cases of intraoral squamous cell carcinoma (OSCC) from the archives of the FOSJC – UNESP Pathology Laboratory, being 30 of floor of the mouth and 30 of tongue, will be analysed in relation to its histological gradation of malignancy. There was a predominance of males in both regions as well as the caucasian race. As for the grading of malignancy, 73.3% of cases of squamous cell carcinoma of tongue and 96.67% of cases of floor were very aggressive. It was noted a mean cell proliferation index increased in cases of floor, however, the difference an compared to the tongue was not statistically significant. Most carcinomas evaluated had no markings for VEGF (63.33% in language and 70% in floor) and positive staining for VEGF-C (73.33% and 79.31% and tongue on the floor). The LDV was greater in cases of tongue, with significant differences between regions. It was found that high values occur in cases of MVD with increased cell proliferation. There was no relation of the growth factors VEGF and VEGF-C with MDV and LDV, respectively... (Complete abstract click electronic access below)

Made available in DSpace on 2014-06-11T19:30:59Z (GMT). No. of bitstreams: 0 Previous issue date: 2006-08-03Bitstream added on 2014-06-13T20:41:01Z : No. of bitstreams: 1 kitakawa_d_dr_sjc.pdf: 747579 bytes, checksum: a564a7ffad24123335cf349a22a13f34 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A carcinogênese em mucosa lingual de rato induzida pela 4-nitroquinolina 1-óxido (4NQO) é um modelo interessante para o estudo da evolução do carcinoma epidermóide fase por fase. Considerando-se que a apoptose tem um papel importante na carcinogênese, o objetivo deste trabalho foi investigar a expressão da survivina, membro da família das proteínas inibidoras de apoptose, através da imunoistoquímica, durante o ensaio de carcinogênese lingual induzida pela 4NQO. Ratos Wistar do sexo masculino foram divididos em três grupos de 10 animais cada e tratados com 50 ppm de 4NQO na água de beber durante quatro, 12 e 20 semanas. Um total de 10 animais foi utilizado como controle negativo. Embora não tenha sido observada alteração histopatológica após 4 semanas de exposição ao carcinógeno, detectou-se survivina no citoplasma das células das camadas granulares e superficiais do epitélio. Nas lesões com atipias após 12 semanas de exposição ao carcinógeno, observou-se survivina citoplasmática apenas na camada superficial do epitélio. Nos carcinomas epidermóides bem diferenciados induzidos após 20 semanas de tratamento com a 4NQO, detectou-se a expressão de survivina citoplasmática nas células adjacentes as pérolas córneas. Não houve imunorreatividade no grupo controle negativo. Diante destes achados, os resultados sugerem que a expressão da survivina citoplasmática é um evento inicial durante a carcinogênese lingual de ratos induzida pela 4NQO, e pode ser uma ferramenta interessante para a identificação de lesões com grande risco de progredir para carcinoma epidermóide das estruturas de revestimento bucal. / 4-nitroquinoline 1-oxide (4NQO)-induced rat tongue carcinogenesis is a useful model for studying the development of squamous cell carcinoma phase by phase. Taking into consideration apoptosis plays an important role in tumorigenesis, the aim of this study was to investigate the expressivity of survivin, a member of the inhibitor apoptotic protein family, during tongue carcinogenesis induced by 4NQO through immunohistochemistry. Male Wistar rats were distributed into three groups of 10 animals each and treated with 50 ppm 4NQO by drinking water for four, 12 or 20 weeks. A total of ten animals were used as negative control. Although no histological changes were induced in the epithelium after 4 weeds of carcinogen exposure, survivin was detected in the cytoplasm within granular and superficial layers. In dysplastic lesions with 12 weeks of carcinogen exposure, cytoplasmic survivin was evidenced in the superficial layer of epithelium only. In well-differetiated squamous cell carcinoma induced after 20 weeks of treatment with 4NQO, cytoplasmic survivin was expressed in some cells adjacent to keratin pearls. No immunoreativity was detected in the negative control group. Taken together, our results suggest that expression of cytoplasmic/nuclear survivin is an early event during 4NQO-induced rat tongue carcinogenesis and may provide a useful toll for the identification of lesions at higher risk of progression into oral squamous cell carcinoma.

INTRODUÇÃO: O carcinoma hepatocelular (CHC) é o mais frequente tipo de câncer primário do fígado e a sua incidência vem aumentando nas últimas décadas, , tornando-o hoje a terceira causa de morte por câncer no mundo. Em cerca de 70 a 80% dos pacientes, o CHC é precedido pelo desenvolvimento de cirrose hepática. Existe um consenso de que a ressecção cirúrgica do tumor é a única terapêutica efetivamente comprovada. Esta ressecção pode ser realizada tanto através de uma hepatectomia como pelo transplante hepático. Atualmente, apenas 30 a 40% dos pacientes se beneficiam dos tratamentos ditos curativos e, mesmo entre esses pacientes, a sobrevida em cinco anos continua baixa, em torno de 60 a 70%, com taxa de recorrência do tumor em torno de 50% em três anos. Alguns estudos mostraram um pior prognóstico para os pacientes com CHC cuja etiologia é a infecção por vírus B ou C. Isso nos leva à questão sobre a existência de uma diferença entre as diversas etiologias do CHC e o seu prognóstico. OBJETIVOS: Comparar o prognóstico (sobrevida global e livre de doença em cinco anos) de pacientes submetidos à hepatectomia para o tratamento do CHC com relação às diversas etiologias da hepatopatia e estudar fatores prognósticos nesse grupo de pacientes. MÉTODO: Foi realizado um levantamento de prontuários dos pacientes submetidos à hepatectomia entre 2000 e 2014 para tratamento de CHC, seguido de análise estatística desse banco de dados, visando a avaliação de parâmetros clínicos, laboratoriais e cirúrgicos. Os pacientes foram divididos em grupos de acordo com a etiologia da hepatopatia, sendo feita uma análise de sobrevida para comparação. RESULTADOS: Não houve diferença estatisticamente significante de prognóstico entre os grupos de pacientes divididos conforme a etiologia do CHC. A sobrevida global e livre de doença em cinco anos dos pacientes dessa amostra foi de 49,9% e 40,7%, respectivamente. As variáveis prognósticas estatisticamente significantes para sobrevida global foram nível sérico de alfafetoproteína (p=0,043), nível sérico de CA19.9 (p=0,028), invasão da cápsula tumoral (p=0,030), margem livre (p=0,004) e presença de complicações pós-operatórias (p < 0,001). CONCLUSÕES: Pelos dados dessa amostra, pudemos constatar que não houve diferença em relação ao prognóstico entre os grupos de pacientes das diversas etiologias de CHC. As variáveis nível sérico de alfafetoproteína e de CA 19.9, invasão da cápsula tumoral, margem livre e complicações pósoperatórias podem ser consideradas preditoras de pior prognóstico / INTRODUCTION: Hepatocellular carcinoma (HCC) is the most frequent type of primary liver cancer and its incidence is increasing around the world in the last decades, making HCC the third cause of death by cancer in the world. In about 70 to 80% of patients, HCC is preceded by cirrhosis of the liver. It is believed that hepatic resection is the single proven curative treatment. This resection can be done in the form of a hepatectomy or liver transplantation. Nowadays, only 30 to 40% of HCC patients can benefit from these curative treatments and, among them, survival in five years is still around 60 to 70%, with tumor recurrence rate around 50% in three years. Some studies have shown a worse prognosis for HCC patients whose etiology is viral. That brings us to the question about the existence of a difference between the various etiologies of HCC and its prognosis. OBJECTIVES: To compare the prognosis (overall and disease-free survival at five years) of patients undergoing hepatectomy for the treatment of HCC with respect to various etiologies of liver disease and to study prognostic factors in this group of patients. METHOD: We performed a review of medical records of patients undergoing hepatectomy between 2000 and 2014 for the treatment of HCC, followed by statistical analysis of this database for evaluation of clinical, laboratory and surgical parameters. Patients were divided into groups according to the etiology of liver disease followed by overall and disease-free survival analysis for comparison. RESULTS: There was no statistically significant difference in the outcomes of the groups of patients divided according to the etiology of HCC. Overall and disease-free survival at five years of patients in this sample was 49.9% and 40.7%, respectively. Statistically significant prognostic variables for overall survival were serum alpha-fetoprotein (p = 0.043), serum CA19.9 (p = 0.028), invasion of the tumor capsule (p = 0.030), resection margins (p = 0.004) and presence of postoperative complications (p < 0.001). CONCLUSIONS: From the data of this sample, we could verify that there was no prognostic differences between the groups of HCC patients of the various etiologies. The variables serum alphafetoprotein and CA 19.9, invasion of the tumor capsule, resection margins and presence of postoperative complications can be considered predictive of worse prognosis